We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Kate
Staniforth
kate.staniforth3@nhs.net
Ms
Alessia
Dunn
alessia.dunn@nhs.net
Dr
James
Alix
j.alix@sheffield.ac.uk
Systemic atrophies primarily affecting the central nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Motor system disorders cause muscle weakness and can be difficult to treat. A potential barrier to testing new treatments can be found in the bridge between measurements made in patients and those performed in research laboratories. For example,different measures of disease are used in those two settings. This increases the uncertainty around the potential of emerging treatments.
Neurophysiological measurements record the electrical activity from the brain and nerves in patients,and also in cells in the laboratory. Thus,these measurements may have the potential to provide a solution.
To test this,we will undertake sophisticated measurements of brain and nerve function in patients being investigated for muscle weakness. We will also take a blood and skin samples and use stem cell technology to create patient specific brain cells that we can study in the laboratory.
Potential patient participants will be identified at the time of referral to the Department of Clinical Neurophysiology. A study invitation letter and participant information sheet will be included with the department appointment ‘ring in’ letter. Participants will then be recruited in clinic.
Our aim is to see if the measurements we take in patients and their cells relate to one another. If they do,this approach may provide a unique platform for testing new treatments for a range of different conditions. This study is funded by the Medical Research Council.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Exclusion criteria: • Any skin condition with areas of inflammation over potential recording sites. • Long term immobilisation (greater than 3 months) caused by a condition other than the primary neurological disorder. • Any implants in head (e.g. aneurysm clips,deep brain stimulators,cochlear implants) or heart (e.g. implantable cardioverter-defibrillator). • Previous stroke. • Pregnancy.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
James
Alix
j.alix@sheffield.ac.uk
Kate
Staniforth
kate.staniforth3@nhs.net
Ms
Alessia
Dunn
alessia.dunn@nhs.net
The study is sponsored by SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 66705
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
